2021 Biotech Stock Picking Charity Contest Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2021 Biotech Stock Picking Charity Contest

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: technetium	11/6/2021 4:18:05 PM
	of 307

Deciphera Pharma Stock Plunges After Disappointing Trial Results (DCPH) finance.yahoo.com Fails primary endpoint in Phase III trials in patients with gastrointestinal stromal tumor (GIST) previously treated with imatinib. No better than standard of care. I like this quote from the CEO: ‘“While we are disappointed with these results, which we learned yesterday, we believe this was a robust, well-designed, and well-executed study," said Steve Hoerter, president and CEO of Deciphera.‘ Many CEO’s would spin it as a failure in the analysis or the selection of patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next